Phase 3CompletedAge-related condition
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
- Sponsor
- GlaxoSmithKline (Industry)
- Enrolment
- 651 enrolled
- Conditions
- Herpes Zoster; Herpes Zoster Vaccine
- Interventions
- Herpes Zoster vaccine (GSK 1437173A)
- Ages
- adults, older adults
- Registry
- NCT02075515, EUCTR2013-000373-76
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Primary outcomes
- Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered